Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Qidong Bufei Decoction is a Traditional Chinese Medicine (TCM) herbal formula primarily developed and studied by researchers at Guang'anmen Hospital, China Academy of Chinese Medical Sciences. It is designed to address postoperative symptoms and improve the quality of life in patients with non-small cell lung cancer (NSCLC). The formula typically follows the TCM principle of "tonifying Qi and nourishing Yin," aiming to alleviate symptoms such as fatigue, cough, and shortness of breath that persist after surgical resection. While the exact composition can vary in clinical practice, it generally includes herbs like *Astragalus membranaceus* and *Ophiopogon japonicus*. Clinical trials have focused on its efficacy in reducing the symptom burden and potentially modulating the immune environment in the recovery phase of lung cancer treatment.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on qidong bufei decoction.